| New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide) |
COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia. TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle. |
globenewswire.com |
2025-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism |
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University (Rome), during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE). |
globenewswire.com |
2025-05-12 20:45:00 |
Czytaj oryginał (ang.) |
| Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 |
COPENHAGEN, Denmark, May 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its hypoparathyroidism, achondroplasia, and growth hormone deficiency (GHD) programs during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) being held May 10-13, 2025, in Copenhagen. |
globenewswire.com |
2025-05-05 12:30:00 |
Czytaj oryginał (ang.) |
| Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript |
Ascendis Pharma A/S (ASND) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Scott Smith - Executive Vice President and Chief Financial Officer Jan Mikkelsen - President and Chief Executive Officer Sherrie Glass - Chief Business Officer Jay Wu - Executive Vice President and President, U.S. Market Aimee Shu - Executive Vice President and Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark Gartner - Evercore ISI Derek Archila - Wells Fargo Joseph Schwartz - Leerink Partners Paul Choi - Goldman Sachs Li Watsek - Cantor Fitzgerald Ellie Merle - UBS Luca Issi - RBC David Lebowitz - Citi Leland Gershell - Oppenheimer Operator Ladies and gentlemen, thank you for standing by and welcome to Ascendis Pharma First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-02 01:35:58 |
Czytaj oryginał (ang.) |
| Ascendis Pharma Reports First Quarter 2025 Financial Results |
- Q1 2025 revenue of €44.7 million for YORVIPATH ® and €51.3 million for SKYTROFA ® - TransCon ™ CNP NDA submitted in Q1 2025; MAA submission planned in Q3 2025 - Topline COACH combination trial ( TransCon CNP + TransCon hGH) data expected in Q2 2025 - Conference call today at 4:30 pm ET COPENHAGEN, Denmark, May 01, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2025, and provided a business update. “The strong global launch of YORVIPATH positions 2025 to be an inflection point for Ascendis with growing revenue and a path to cashflow breakeven in the near term,” said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. |
globenewswire.com |
2025-05-01 20:01:00 |
Czytaj oryginał (ang.) |
| Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 |
COPENHAGEN, Denmark, April 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2025 financial results and provide a business update on Thursday, May 1, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 1, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2025 financial results. |
globenewswire.com |
2025-04-24 20:01:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? |
Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year. |
zacks.com |
2025-04-16 14:46:33 |
Czytaj oryginał (ang.) |
| Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory |
Shares of ASND have fared well during recent market volatility and the downturn in the biotech sector. Setbacks for competitors in PTH (hypoparathyroidism) paves the way for successful Yorvipath launch with long runway to maximize peak sales potential. Management is wisely focusing on applying TransCon technology to rare disease markets while partnering out applications in other areas such as obesity. |
seekingalpha.com |
2025-04-14 20:38:58 |
Czytaj oryginał (ang.) |
| Ascendant Resources Notifies Shareholders Of Upcoming Special Meeting |
TORONTO, ON / ACCESS Newswire / April 14, 2025 / Further to its press release on February 3, 2025, Ascendant Resources Inc. (the "Company" or "Ascendant") (TSX:ASND) announces that it has mailed and filed on SEDAR+ its notice of meeting and management information circular (the "Meeting Materials") in respect of the upcoming special meeting ("Meeting") of shareholders of the Company (the "Shareholders"). The Meeting will be held at the offices of the Company, 200 Bay Street, Suite 3205, Toronto, Ontario, Canada, M5J 2J2 on May 6, 2025 at 10:00 a.m. |
accessnewswire.com |
2025-04-14 10:30:00 |
Czytaj oryginał (ang.) |
| Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia |
— Data demonstrated multiple clinical benefits beyond linear growth — NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years of open-label extension data — MAA in EU on track for submission during Q3 2025 COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon CNP (navepegritide) for the treatment of children with achondroplasia. TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to treat individuals with achondroplasia by providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle. |
globenewswire.com |
2025-03-31 20:01:00 |
Czytaj oryginał (ang.) |
| Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock? |
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2025-03-18 12:50:35 |
Czytaj oryginał (ang.) |
| Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference |
COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts. |
globenewswire.com |
2025-02-24 18:01:00 |
Czytaj oryginał (ang.) |
| Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? |
On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros. |
benzinga.com |
2025-02-13 16:40:30 |
Czytaj oryginał (ang.) |
| Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript |
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Yaron Werber - TD Cowen Joori Park - Leerink Kelly Shi - Jefferies Ellie Merle - UBS David Lebowitz - Citi Paul Choi - Goldman Sachs Alex Thompson - Stifel Yun Zhong - Wedbush Securities Operator Good day and thank you for standing by. Welcome to the Fourth Quarter and Full Year 2024 Ascendis Pharma Earnings Conference Call. |
seekingalpha.com |
2025-02-13 01:03:44 |
Czytaj oryginał (ang.) |
| Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs |
– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares |
globenewswire.com |
2025-02-12 18:05:00 |
Czytaj oryginał (ang.) |
| Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results |
– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million |
globenewswire.com |
2025-02-12 18:01:00 |
Czytaj oryginał (ang.) |
| Ascendant Resources Announces Closing of First Tranche of Private Placement |
• Funds to Progress Lagoa Salgada Project and extinguish a significant portion of short-term payables • Additional Support Received for Arrangement with Cerrado NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / February 11, 2025 / Ascendant Resources Inc. (TSX:ASND) ("Ascendant" or the "Company") is pleased to announce closing of the first tranche ("First Tranche(TSX:ASND) ("Ascendant" or the "Company") is pleased to announce closing of the first tranche ("First Tranche") of the private placement (the "Placement") previously announced on February 3, 2025 in connection with the arrangement agreement (the "Arrangement Agreement") it entered into with Cerrado Gold Inc. ("Cerrado"), whereby Cerrado has agreed to acquire all of the issued and outstanding common shares of Ascendant (each an "Ascendant Share") by way of a plan of arrangement (the "Arrangement"). Under the First Tranche, the Company has issued 45,047,617 Ascendant Shares at the price of C$0.0525 per Ascendant Share for gross proceeds of approximately C$2.365 million through a combination of cash and the satisfaction of outstanding debt. |
accessnewswire.com |
2025-02-11 19:00:00 |
Czytaj oryginał (ang.) |
| Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 |
COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results. |
globenewswire.com |
2025-02-05 18:01:00 |
Czytaj oryginał (ang.) |
| Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade) |
TransCon CNP matches BioMarin's Voxzogo for achondroplasia with weekly vs daily dosing; regulatory filings planned for 2025. Commercial products Skytrofa and Yorvipath growing steadily, with Q3 revenue of $62.4M; validates TransCon platform technology. Novo deal for monthly GLP-1 in obesity could be game-changing; includes $285M in milestones plus royalties and expansion options. |
seekingalpha.com |
2025-01-29 13:25:45 |
Czytaj oryginał (ang.) |
| Ascendis Pharma: Danish Blockbuster Hunter |
Ascendis Pharma has piqued my interest due to its promising developments and strong pipeline. The company boasts several commercial stage products, indicating a robust foundation and growth potential. Ascendis' diverse pipeline supports a positive investment thesis, suggesting significant future advancements and market opportunities. |
seekingalpha.com |
2025-01-29 02:31:25 |
Czytaj oryginał (ang.) |